This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis (BSX-003)

This study has been terminated.
Information provided by:
Cerimon Pharmaceuticals Identifier:
First received: March 26, 2008
Last updated: August 17, 2010
Last verified: August 2010
The objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis.

Condition Intervention Phase
Non-infectious Uveitis Drug: Basiliximab Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Masked, Placebo-controlled Evaluation of the Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis Who Undergo Tapering of Concomitant Immunosuppressive Medications

Resource links provided by NLM:

Further study details as provided by Cerimon Pharmaceuticals:

Primary Outcome Measures:
  • To prevent an increase in disease activity as measured by anterior cell count, vitreal haze and visual acuity while subjects with stable noninfectious uveitis undergo tapering of concomitant immunosuppressive medications [ Time Frame: The primary outcome will be assessed at Week 16 ]

Secondary Outcome Measures:
  • Secondary objectives are to assess changes in visual acuity, retinal thickness, corticosteroid dose, and immunosuppressive drug score. Basiliximab pharmacokinetics and immunogenicity will also be assessed [ Time Frame: These measures will be assessed at Week 16 ]

Enrollment: 5
Study Start Date: May 2008
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Basiliximab
40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
Other Name: Simulect
Placebo Comparator: 2 Drug: Placebo
Placebo to match basiliximab


Ages Eligible for Study:   12 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of noninfectious intermediate, posterior or panuveitis of at least 3 months duration
  • Treatment with greater than or equal to 20 mg/day of Prednisone at baseline or immunosuppressive drug score of greater than or equal to 5 at baseline
  • BCVA by ETDRS protocol better than or equal to 20/200
  • Intraocular pressure of 24 mmHg or less
  • Anterior chamber cells and vitreous haze of less than or equal to 1
  • Male or females, aged 12 or greater, body weight of 40 kg or greater

Exclusion Criteria:

  • Prior treatment with Retisert
  • Primary diagnosis of anterior uveitis, uveitis of infectious etiology or Behcet's disease
  • Pregnancy or breast-feeding
  • Increase in systemic immunosuppressive treatment regimen within 6 weeks before baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00646425

United States, Massachusetts
Ocular Immunology & Uveitis Foundation
Cambridge, Massachusetts, United States, 02142
United States, Missouri
Tauber Eye Center
Kansas City, Missouri, United States, 64111
United States, New York
New York Eye and Ear Infirmary
New York, New York, United States, 10003
United States, North Carolina
Southeast Clinical Research Associates
Belmont, North Carolina, United States, 28012
United States, Texas
University of Texas Medical Branch
Galveston, Texas, United States, 77555
Vitreoretinal Consultants
Houston, Texas, United States, 77030
Sponsors and Collaborators
Cerimon Pharmaceuticals
Study Director: Shaily Reichert Cerimon Pharmaceuticals
  More Information

Responsible Party: Shaily Reichert, Cerimon Pharmaceuticals Identifier: NCT00646425     History of Changes
Other Study ID Numbers: BSX-003
Study First Received: March 26, 2008
Last Updated: August 17, 2010

Keywords provided by Cerimon Pharmaceuticals:
Non-infectious uveitis

Additional relevant MeSH terms:
Uveal Diseases
Eye Diseases
Antibodies, Monoclonal
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on August 22, 2017